Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVJF) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Teva Pharmaceutical Industries (TEVJF) over the last 17 years, with Q4 2025 value amounting to $51.0 million.

  • Teva Pharmaceutical Industries' Share-based Compensation rose 5000.0% to $51.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $157.0 million, marking a year-over-year increase of 2764.23%. This contributed to the annual value of $157.0 million for FY2025, which is 2764.23% up from last year.
  • Teva Pharmaceutical Industries' Share-based Compensation amounted to $51.0 million in Q4 2025, which was up 5000.0% from $34.0 million recorded in Q3 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' Share-based Compensation peaked at $51.0 million during Q4 2025, and registered a low of $24.0 million during Q1 2022.
  • Moreover, its 5-year median value for Share-based Compensation was $31.5 million (2021), whereas its average is $32.2 million.
  • Per our database at Business Quant, Teva Pharmaceutical Industries' Share-based Compensation crashed by 2307.69% in 2023 and then skyrocketed by 5000.0% in 2025.
  • Quarter analysis of 5 years shows Teva Pharmaceutical Industries' Share-based Compensation stood at $33.0 million in 2021, then rose by 9.09% to $36.0 million in 2022, then decreased by 22.22% to $28.0 million in 2023, then rose by 21.43% to $34.0 million in 2024, then skyrocketed by 50.0% to $51.0 million in 2025.
  • Its last three reported values are $51.0 million in Q4 2025, $34.0 million for Q3 2025, and $38.0 million during Q2 2025.